Kiadis Pharma to present at Biotech Showcase 2019
03 Janvier 2019 - 7:00AM
Kiadis Pharma to
present at Biotech Showcase 2019
Amsterdam, The
Netherlands, January 3, 2019 - Kiadis Pharma N.V. ("Kiadis Pharma"
or the "Company") (Euronext Amsterdam and Brussels: KDS), a
clinical-stage biopharmaceutical company, today announces that it
is scheduled to present at the Biotech Showcase(TM) 2019 at the
Hilton San Francisco Union Square in January 2019.
Biotech Showcase 2019
January 7-9,
2019
Hilton San Francisco Union Square Hotel, 333
O'Farrell Street, San Francisco, CA
Hilton/Yosemite A, Ballroom Level
Arthur Lahr, CEO, will present on Monday, January 7 at 3:30pm
PST.
The Kiadis management team will also host
one-on-one meetings from January 7-10 in San Francisco.
For more
information, please contact:
Kiadis Pharma:
Scott Holmes
Chief Financial Officer
s.holmes@kiadis.com
|
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 950 9144
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
|
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical (genetically
half-matched) hematopoietic stem-cell transplantations (HSCT) for
adult blood cancers to address key limitations of haploidentical
HSCT, without prophylactic immunosuppression and its associated
morbidity and mortality. Based on the positive results from the
single dose Phase 2 CR-AIR-007 study, the Company submitted a
marketing authorization application to the European Medicines
Agency in April 2017 for approval of ATIR101 as an adjunctive
treatment in haploidentical HSCT for high risk adult hematological
malignancies. If the product is conditionally approved, Kiadis
Pharma intends to launch ATIR101 through its own commercial
organization in a first EU member state in the second half of
2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase 3 clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, (PTCy) protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy (RMAT) designation from the FDA in
September 2017, which provides benefits that are materially
equivalent to a Breakthrough Therapy designation from the FDA. In
addition, ATIR101 has been granted multiple orphan drug
designations both in the European Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, regulation, competition and
technology, can cause actual events, performance or results to
differ significantly from any anticipated development. Forward
looking statements contained in this press release regarding past
trends or activities should not be taken as a representation that
such trends or activities will continue in the future. As a result,
Kiadis Pharma expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements
in this press release as a result of any change in expectations or
any change in events, conditions, assumptions or circumstances on
which these forward-looking statements are based. Neither Kiadis
Pharma nor its advisers or representatives nor any of its
subsidiary undertakings or any such person's officers or employees
guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking
statements contained in this press release or the actual occurrence
of the forecasted developments. You should not place undue reliance
on forward-looking statements, which speak only as of the date of
this press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire